Advanced

Novel markers of normal and neoplastic human plasmacytoid dendritic cells

Marafioti, Teresa; Paterson, Jennifer C; Ballabio, Erica; Reichard, Kaaren K; Tedoldi, Sara; Hollowood, Kevin; Dictor, Michael LU ; Hansmann, Martin-Leo; Pileri, Stefano A and Dyer, Martin J, et al. (2008) In Blood 111(7). p.3778-3792
Abstract
Plasmacytoid dendritic cells (pDCs) are involved in innate immunity (eg, by secreting interferons) and also give rise to CD4(+)CD56(+) hematodermic neoplasms. We report extensive characterization of human pDCs in routine tissue samples, documenting the expression of 19 immunohistologic markers, including signaling molecules (eg, BLNK), transcription factors (eg, ICSBP/IRF8 and PU.1), and Toll-like receptors (TLR7, TLR9). Many of these molecules are expressed in other cell types (principally B cells), but the adaptor protein CD2AP was essentially restricted to pDCs, and is therefore a novel immunohistologic marker for use in tissue biopsies. We found little evidence for activation-associated morphologic or phenotypic changes in conditions... (More)
Plasmacytoid dendritic cells (pDCs) are involved in innate immunity (eg, by secreting interferons) and also give rise to CD4(+)CD56(+) hematodermic neoplasms. We report extensive characterization of human pDCs in routine tissue samples, documenting the expression of 19 immunohistologic markers, including signaling molecules (eg, BLNK), transcription factors (eg, ICSBP/IRF8 and PU.1), and Toll-like receptors (TLR7, TLR9). Many of these molecules are expressed in other cell types (principally B cells), but the adaptor protein CD2AP was essentially restricted to pDCs, and is therefore a novel immunohistologic marker for use in tissue biopsies. We found little evidence for activation-associated morphologic or phenotypic changes in conditions where pDCs are greatly increased (eg, Kikuchi disease). Most of the molecules were retained in the majority of pDC neoplasms, and 3 (BCL11A, CD2AP, and ICSBP/IRF8) were also commonly negative in leukemia cutis (acute myeloid leukemia in the skin), a tumor that may mimic pDC neoplasia. In summary, we have documented a range of molecules (notably those associated with B cells) expressed by pDCs in tissues and peripheral blood (where pDCs were detectable in cytospins at a frequency of < 1% of mononuclear cells) and also defined potential new markers (in particular CD2AP) for the diagnosis of pDC tumors. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Blood
volume
111
issue
7
pages
3778 - 3792
publisher
American Society of Hematology
external identifiers
  • wos:000254569300067
  • scopus:43549106155
ISSN
1528-0020
DOI
10.1182/blood-2007-10-117531
language
English
LU publication?
yes
id
e55014dd-711e-4506-8c28-5a56a42661dd (old id 1182711)
date added to LUP
2008-09-01 15:36:12
date last changed
2017-11-12 03:24:46
@article{e55014dd-711e-4506-8c28-5a56a42661dd,
  abstract     = {Plasmacytoid dendritic cells (pDCs) are involved in innate immunity (eg, by secreting interferons) and also give rise to CD4(+)CD56(+) hematodermic neoplasms. We report extensive characterization of human pDCs in routine tissue samples, documenting the expression of 19 immunohistologic markers, including signaling molecules (eg, BLNK), transcription factors (eg, ICSBP/IRF8 and PU.1), and Toll-like receptors (TLR7, TLR9). Many of these molecules are expressed in other cell types (principally B cells), but the adaptor protein CD2AP was essentially restricted to pDCs, and is therefore a novel immunohistologic marker for use in tissue biopsies. We found little evidence for activation-associated morphologic or phenotypic changes in conditions where pDCs are greatly increased (eg, Kikuchi disease). Most of the molecules were retained in the majority of pDC neoplasms, and 3 (BCL11A, CD2AP, and ICSBP/IRF8) were also commonly negative in leukemia cutis (acute myeloid leukemia in the skin), a tumor that may mimic pDC neoplasia. In summary, we have documented a range of molecules (notably those associated with B cells) expressed by pDCs in tissues and peripheral blood (where pDCs were detectable in cytospins at a frequency of &lt; 1% of mononuclear cells) and also defined potential new markers (in particular CD2AP) for the diagnosis of pDC tumors.},
  author       = {Marafioti, Teresa and Paterson, Jennifer C and Ballabio, Erica and Reichard, Kaaren K and Tedoldi, Sara and Hollowood, Kevin and Dictor, Michael and Hansmann, Martin-Leo and Pileri, Stefano A and Dyer, Martin J and Sozzani, Silvano and Dikic, Ivan and Shaw, Andrey S and Petrella, Tony and Stein, Harald and Isaacson, Peter G and Facchetti, Fabio and Mason, David Y},
  issn         = {1528-0020},
  language     = {eng},
  number       = {7},
  pages        = {3778--3792},
  publisher    = {American Society of Hematology},
  series       = {Blood},
  title        = {Novel markers of normal and neoplastic human plasmacytoid dendritic cells},
  url          = {http://dx.doi.org/10.1182/blood-2007-10-117531},
  volume       = {111},
  year         = {2008},
}